FDA expands indication for use of abemaciclib with early, high-risk breast cancer

Abemaciclib (Verzenio) with endocrine therapy (tamoxifen or an aromatase inhibitor) is now approved for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at high risk for recurrence, the U.S. Food and Drug Administration announced on March 3.

Leave A Comment

Your email address will not be published. Required fields are marked *